ASCO Boosts AstraZeneca’s Standings, And Options
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm’s head oncology strategist says positive data released at the American Society of Clinical Oncology was not included in financial forecasts provided a month ago while AstraZeneca fought off Pfizer’s takeover attempt.